Avalo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports third quarter revenue of zero dollars
Avalo Therapeutics Inc. reported cash, cash equivalents, and short-term investments of $111.6 million as of September 30, 2025. Net cash used in operating activities was $37.2 million for the nine months ended September 30, 2025. The company expects its current cash resources to fund operations into 2028. Product revenue for the third quarter and nine months ended September 30, 2025, was zero, compared to $0.2 million for the same periods in 2024. Recent business developments include the completion of enrollment in the Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa, with topline data expected in mid-2026, and the appointment of Kevin Lind to the Board of Directors, as well as new leadership in business development and human resources.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569770-en) on November 06, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。